Drug maker Bayer AG and biotech venture-capital firm Versant Ventures are investing $225-million to create a Toronto-based stem-cell research company, a move with the potential to establish Canada as a global centre for the commercialization of regenerative-medicine therapies.
https://beta.theglobeandmail.com/report-on-business/bayer-ag-investing-in-toronto-based-stem-cell-research-company/article33292430/?ref=http://www.theglobeandmail.com&